Argenx To Discontinue Phase 3 UNITY Study Of Efgartigimod In Sjgren's Disease

October 08, 2026 — 01:40 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - argenx SE (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate-to-severe Sjgren's disease. Following interim analysis, an Independent Data Monitoring Committee concluded that the UNITY study is unable to meet its primary endpoint, and hence recommended to stop the study.

Separately, argenx announced positive topline results from the Phase 2 study evaluating FB102 in adults with celiac disease. Patients treated with FB102 showed a statistically significant and clinically relevant treatment effect compared to placebo. The study met primary endpoint of change from baseline in the ratio of villus heighttocrypt depth at day 78 versus placebo in adults with celiac disease undergoing a gluten challenge. The company plans to advance FB102 into Phase 3 development.

At last close on NasdaqGS, argenx shares were trading at $928.44.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Argenx To Discontinue Phase 3 UNITY Study Of Efgartigimod In Sjgren's Disease

Tags

Latest Articles